# A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects

> **NCT02798978** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 42 (actual)

## Conditions studied

- Cancer
- Neoplasms

## Interventions

- **DRUG:** GSK1795091
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02798978
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-10
- **Primary completion:** 2017-10-13
- **Final completion:** 2017-10-13
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2020-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02798978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02798978, "A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02798978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*